Posted by Michael Wonder on 10 Jun 2026
Matisse Pharmaceuticals receives FDA fast track designation for isupartob sodium in sepsis
9 June 2026 - Matisse Pharmaceuticals today announced that the US FDA has granted fast track designation for its lead compound isupartob sodium.
The news follows Matisse’s announcement of IND clearance of isupartob on 19 May 2026.
